Therapeutic Considerations in Metastatic HER2+ Breast Cancer: Part 1

Publication
Article
Supplements and Featured PublicationsTherapeutic Considerations in Metastatic HER2+ Breast Cancer: Part 1
Volume 1
Issue 1

This publication includes a summary of data on recent therapeutic advances in treating metastatic HER2-positive breast cancer that was presented during a series of 4 live regional broadcasts across the United States (California, Illinois, Texas, and Washington). Medical oncologists specializing in the treatment of breast cancer across those regions provide key insights on factors that influence planning and treatment selection.

Download Issue PDF
Articles in this issue
breast cancer
Therapeutic Considerations in Metastatic HER2+ Breast Cancer: Part 1
Related Videos
Samer A. Srour, MB ChB, MS
Julia Foldi, MD, PhD
Video 4 - "The Evolving Treatment Landscape with CDK4/6 Inhibitors in Early HR+/HER2- Breast Cancer"
Margaret E. Gatti-Mays, MD, MPH, FACP, of The Ohio State University Comprehensive Cancer Center
Samer A. Srour, MB ChB, MS
Núria Agustí Garcia, MD
Alessandra Ferrajoli, MD
Sangeeta Goswami, MD, PhD, of The University of Texas MD Anderson Cancer Center
Ko Un “Clara” Park, MD
Erin Frances Cobain, MD
Related Content
Breast Cancer | adobe.stock.com

Durvalumab Plus Trastuzumab/Pertuzumab Elicits Responses in HER2-Enriched Breast Cancer

April 16th 2024
Article
D. Ross Camidge, MD, PhD; B.J. Rimel, MD, assistant professor, obstetrics and gynecology, Cedars-Sinai, medical director, Cancer Clinical Trials Office, Cedars-Sinai Cancer Institute, health sciences associate clinical professor, Department of Obstetrics and Gynecology, University of California, Los Angeles

Camidge and Rimel on the Importance of Cultivating Inclusive Gynecologic Oncology Practices

April 15th 2024
Podcast
Matt Coffey, PhD, president, chief executive officer, Oncolytics Biotech

FDA Receives Type C Meeting Request for Pelareorep in HR+/HER2– Metastatic Breast Cancer

April 12th 2024
Article
Stephanie L. Graff, MD, director, Breast Oncology, Lifespan Cancer Institute, associate professor, medicine, Brown University; Reshma L. Mahtani, DO, medical oncologist, Miami Cancer Institute, chief, Breast Medical Oncology, Baptist Health’s Wellness and Medical Complex; Kelly E. McCann, MD, PhD, breast medical oncologist, assistant clinical professor, medicine, the University of California, Los Angeles Health David Geffen School of Medicine; Hope S. Rugo, MD, Winterhof Family Endowed Professor in Breast Cancer, the University of California San Francisco (UCSF), professor, medicine, Division of Hematology and Oncology, director, Breast Oncology, director, Clinical Trials Education, director, Cancer Infusion Services, the UCSF Helen Diller Family Comprehensive Cancer Center

Breast Cancer Experts Share Obstacles and Successes as Women in Oncology

April 11th 2024
Podcast
Aiham Qdaisat, MD, of MD Anderson Cancer Center

Breast-Conserving Therapy Bests Mastectomy After Preoperative Systemic Therapy in HER2+ Breast Cancer

April 9th 2024
Article
Jonathan T. Yang, MD

AZD1390 Demonstrates Initial Safety, May Enhance Radiotherapy Efficacy in Glioblastoma

April 9th 2024
Article